Mendus AB

Equities

IMMU

SE0022239950

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2025-12-05 EST			5-day change	1st Jan Change
5.080 ^SEK	+0.20%		-0.39%	-34.88%

12-01	Mendus establishes large-scale GMP production for vididencel	FW
11-27	Mendus Reports Positive Long-Term Data for Vididencel in Ovarian Cancer	FW

Mendus AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025

Published on 11/13/2025 at 10:31 am EST - Modified on 11/13/2025 at 02:00 am EST

S&P Capital IQ

Mendus AB

+0.20%

Mendus AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2025. For the third quarter, the company reported net loss was SEK 19.01 million compared to SEK 23.03 million a year ago. Basic loss per share from continuing operations was SEK 0.37 compared to SEK 0.46 a year ago.
For the nine months, net loss was SEK 72.18 million compared to SEK 96.88 million a year ago. Basic loss per share from continuing operations was SEK 1.41 compared to SEK 2.02 a year ago.

Latest news about Mendus AB

12-01	Mendus establishes large-scale GMP production for vididencel	FW
11-27	Mendus Reports Positive Long-Term Data for Vididencel in Ovarian Cancer	FW
11-27	Mendus AB announces positive 2-year follow-up data from Alison trial	RE
11-27	Mendus AB Announces Positive 2-Year Follow-Up Data from the Alison Phase 1 Trial	CI
11-19	Stockholm Bullets - Viscaria falls after announcing terms of issue	FW
11-19	Mendus raises SEK 52.5 million through directed share issue	RE
11-19	Mendus Conducts Directed Share Issue of SEK 52.5 Million at a 9.7 Percent Discount	FW
11-18	Mendus Plans Directed Share Issue of Approximately SEK 50 Million	FW
11-13	Mendus AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	Mendus AB, Q3 2025 Earnings Call, Nov 13, 2025
11-13	Mendus Reports Reduced Operating Loss in Third Quarter	FW
10-28	Mendus board member Helén Tuvesson increases her shareholding	FW
10-24	Mendus Chairman Sven Andreasson Increases His Shareholding	FW
10-24	Mendus Board Member Hans Preusting Increases His Shareholding	FW
10-06	Redeye Lowers Target Price for Mendus to 17 SEK per Share	FW
10-06	Redeye Lowers Fair Value Estimate for Mendus to 17 Kronor (Previously 27)	FW
10-02	Stockholm Bullets - Hansa Biopharma declines after a major targeted new share issue	FW
10-02	Mendus Updates Development Strategy for Vididencel, Reduces Workforce	FW
10-02	Mendus announces updated clinical strategy, operational focus	RE
10-02	Mendus AB Announces Executive Changes	CI
10-02	Mendus AB Announces an Update of the Late-Stage Clinical Development Strategy with its Lead Product Vididencel in Myeloid Malignancies	CI
08-21	Mendus AB, Q2 2025 Earnings Call, Aug 21, 2025
08-21	Mendus AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
08-21	Mendus Reports Reduced Operating Loss in Second Quarter	FW
08-21	Mendus Approves Transfer of Up to 1.2 Million Shares	FW

Chart Mendus AB

Duration

Period

IMMU: Dynamic Chart

Company Profile

Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patientâs own immune system against cancer. The Companyâs programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.

Employees

Sector

Biotechnology & Medical Research

Calendar

12-16 - Extraordinary Shareholders Meeting

More about the company